Wells Fargo raised the firm’s price target on ShockWave Medical to $335 from $210 and keeps an Equal Weight rating on the shares following quarterly results. The firm notes sales of $219M exceeded its prior estimate by about $9M, with larger part of the beat driven by coronary and outside U.S. Gross margin of 87.1% was about in-line and opex of $148.2M was also in-line with Wells’ estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWAV:
- Shockwave Medical’s High Stakes: The Cost of a Collapsed Johnson & Johnson Merger
- ShockWave Medical reports Q1 diluted EPS $1.44, consensus 98c
- Shockwave Medical Reports First Quarter 2024 Financial Results
- SWAV Earnings this Week: How Will it Perform?
- Shockwave Medical Merges with Johnson & Johnson, Retains Key Leader